EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.85), $0.04 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $6.66 million.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform
- Evolution Petroleum to buy Midland Basin mineral rights for $16M
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
